Investor Presentaiton slide image

Investor Presentaiton

Business model with cost and synergy advantages Only integrated player in the region with significant cost advantage in scale and synergies Financial metrics (GEL m) 1Q17 4Q17 1Q18 Number of hospitals 35 37 37 Number of beds 2,731 3,014 3,320 Number of polyclinics 13 16 17 Number of pharmacies 245 255 256 Bed occupancy rate, referral hospitals 68.1% 60.4% 65.7% * FY16 includes only May-Dec GPC's results Annual Quarterly Revenue EBITDA 2015 246 2016 2017 1017 1Q18 450.00 426 748 186 208 400.00 56 78 108 25 31 GBP 1.70 350.00 Profit before tax 24 40 46 13 16 IPO price 300.00 Healthcare EBITDA margin 27.4% 30.2% 26.4% 25.3% 25.2% 250.00 Pharma EBITDA margin N/A 4.3%* 8.6% 7.8% 10.0% 200.00 Selected operating metrics 150.00 100.00 Healthcare and pharmacy business (GHG) overview Market Leader 26.4% market share by number of beds (3,320) ■ 30% market share by Pharma sales. Key facts The widest population coverage: over 3/4 of Georgia's 3.7mln population Long-term high-growth opportunities GEORGIA HEALTHCARE GROUP Market opportunity Total healthcare market (including healthcare services and pharmacy) GEL million GEORGIA CAPITAL 6,000 5,000 Very low base: healthcare services spending per capita only US$ 325 4,000 Growing market: healthcare spending growing at 11.5% CAGR 2000-2014 3,000 ■ Implying long-term, high-growth expansion driven by potential to develop medical tourism and Polyclinics (outpatient clinics) 2,000 Total Market CAGR 2011-2016 of 16% 1,552 1,716 2,034 3,062 3,218 Total Market CAGR 2017-2021 of 8% 3,760 4,062 4,397 3,488 4,765 2,464 1,000 0 Nov-15 Jan-16 Mar-16 May-16 Jul-16 Sep-16 Nov-16 Exit Strategy - Sell downs/Block trades In May 2017 Georgia Capital sold 9.5 million shares of GHG (7.2%) for US$ 40 million Georgia Capital's stake in GHG is currently at 57% 2011 2012 2013 2014 2015 2016 2017F 2018F 2019F 2020F 2021F Source: Frost & Sullivan analysis 2017 Stock price performance Jan-17 Mar-17 May-17 Jul-17 Sep-17 Nov-17 GBP 2.65 as of 10-May-2018 Jan-18 Mar-18 May-18 Page 20
View entire presentation